Want to join the conversation?
$K expects full-year cash flow from operating activities to be about $1.7Bil. $K reaffirmed its full-year cash flow outlook to be about $1.1Bil, including capital expenditure. Capital expenditure is still expected to be 4-5% of sales, which translates about into $525-$625MM.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.